AMGN vs NVS
Amgen and Novartis AG, both Healthcare
Novartis AG is the larger company at $281B against $182B. On trailing earnings NVS is the cheaper of the two at a P/E of 23.3 against 27.4, a gap that is only a bargain if the two are growing at similar rates. Over the past year AMGN returned +59% against +40% for NVS. Ryufin's sector-relative Smart Score puts AMGN ahead, 9/10 against 8/10.
| Figure | AMGN | NVS |
|---|---|---|
| Last close | $440 | $158 |
| Market cap | $182B | $281B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 27.4 | 23.3 |
| Dividend yield | 2.2% | n/a |
| 1-year return | +59% | +40% |
| 5-year return | +113% | +106% |
| Ryufin Smart Scoresector-relative, 1–10 | 9/10 | 8/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Amgen
Revenue of $10B in Q2 2026, net income $2.4B. Its largest reported line is Other Products, 17% of the disclosed total.
Novartis AG
Revenue of $27B in H2 2025, net income $6.3B.
Open these two in the interactive comparison to add more names, change the period or read the correlation.